CSL shares are being hammered

German Chancellor Angela Merkel. John MacDougall/AFP/Getty Images)

Shares CSL dropped hard after the blood products company posted a 10% fall in full year net profit to $US1.24 billion ($A1.6 billion).

In early trade, they were down almost 8% to $A107.56.

The top 10 Australian company by market capitalisation last year became the world’s second largest flu vaccine business by buying a loss-making subsidiary of Swiss pharmaceutical multinational Novartis for $US275 million ($A357 million).

Without the costs of that purchase, and adjusting for currency fluctuations, underlying net profit after tax was up 5.2% to $US1.47 billion ($A1.9 billion).

The flu vaccine business is due to break even in 2018.

Revenue at the 100-year-old company increased by almost 9% to $US6.13 billion (almost $A8 billion).

For 2017, CEO Paul Perreault forecasts 11% profit growth and a 14% rise in EBITDA (earnings before interest, tax, depreciation and amortisation).

A final dividend of $US0.68 a share, up 3%, was declared.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.